<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417390</url>
  </required_header>
  <id_info>
    <org_study_id>FSHNG-1108</org_study_id>
    <nct_id>NCT01417390</nct_id>
  </id_info>
  <brief_title>Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Foshan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus
      concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with
      locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of
      induction chemotherapy using gemcitabine and cisplatin in NPC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presented with non-keratinizing NPC and stage Ⅲ-Ⅳb T3-4N1M0/TxN2-3M0 are randomly
      assigned to receive induction chemotherapy (gemcitabine+cisplatin) plus concurrent
      chemoradiotherapy (investigational arm) or concurrent chemoradiotherapy (control arm).
      Patients in both arms receive radical Intensity modulated radiation therapy (Trilogy,
      Varian), and cisplatin (40mg/m2) every weeks for six cycles during radiotherapy. Radiation is
      delivered to GTV at 70 Gy in 30 fractions, CTV1 at at 60 Gy in 30 fractions and CTV2 at 54 Gy
      in 30 fractions. Patients in the investigational arm receive gemcitabine (1000mg/m2 on day
      1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the
      radiotherapy. The primary end point is response rates after radiotherapy, failure-free
      survival (FFS) and toxic effects and treatment compliance. Secondary end points include
      overall survival (OS), distant failure-free survival (D-FFS), locoregional failure-free
      survival (LR-FFS). All efficacy analyses are conducted in the intention-to-treat population;
      the safety population include only patients who receive their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Failure-free survival is calculated from the date of randomization to the date of the first failure at any site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>the latency to the first local failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>The latency to the first remote failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The initial response rates after treatments</measure>
    <time_frame>16 weeks after completion of radiotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inductive and concurrent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Gemcitabine and cisplatin</intervention_name>
    <description>Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.</description>
    <arm_group_label>Inductive and concurrent</arm_group_label>
    <other_name>Gemcitabine and cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy</description>
    <arm_group_label>Concurrent chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing (according to World
             Health Organization (WHO 2005) histologically type).

          -  Karnofsky scale (KPS) &gt; 70.

          -  Tumor staged is according to the 7th American Joint Commission on Cancer edition as
             Stage III：T1-2N2M0, T3N0-2M0 Stage IVa：T4N0-2M0 Stage IVb：Any T、N3.

          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count
             ≥100000/μL.

          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
             ≤2.5×ULN, and bilirubin ≤ULN.

          -  Adequate renal function: creatinine clearance ≥60 ml/min.

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent.

        Exclusion Criteria:

          -  WHO Type keratinizing squamous cell carcinoma.

          -  Age &gt;60 years or &lt;18 years.

          -  Treatment with palliative intent.

          -  Pregnancy or lactation.

          -  Prior radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or
             nodes.

          -  Any severe intercurrent disease including unstable cardiac disease, chronic hepatitis,
             renal disease, diabetes with poor control, and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei wei Hong, M.D.</last_name>
    <phone>+86-757-83162835</phone>
    <email>wwhong@fsyyy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wei-wei Hong</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei wei Hong, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Tao Xu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>He X, Ou D, Ying H, Zhu G, Hu C, Liu T. Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2012 Mar;269(3):1027-33. doi: 10.1007/s00405-011-1669-9. Epub 2011 Jun 26. Erratum in: Eur Arch Otorhinolaryngol. 2012 Mar;269(3):1035. Xiayun, He [corrected to He, Xiayun]..</citation>
    <PMID>21706324</PMID>
  </reference>
  <reference>
    <citation>Drössigk U, Hiepe T, Pötzsch F, Scholz D, Tietz HJ. Stimulation of human immunodeficiency virus expression in permanent monocytic cells by Sarcocystis gigantea extract. Parasitol Res. 1998 Jun;84(6):455-8.</citation>
    <PMID>9660134</PMID>
  </reference>
  <reference>
    <citation>Lowy AM, Firdaus I, Roychowdhury D, Redmond K, Howington JA, Sussman JJ, Safa M, Ahmad SA, Reed MF, Rose P, James L, Jazieh AR. A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma. Am J Clin Oncol. 2006 Dec;29(6):555-61.</citation>
    <PMID>17148991</PMID>
  </reference>
  <reference>
    <citation>Yau TK, Lee AW, Wong DH, Yeung RM, Chan EW, Ng WT, Tong M, Soong IS. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck. 2006 Oct;28(10):880-7.</citation>
    <PMID>16721741</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol. 2005 Oct;28(5):464-71.</citation>
    <PMID>16199985</PMID>
  </reference>
  <reference>
    <citation>Benasso M, Merlano M, Sanguineti G, Corvò R, Numico G, Ricci I, Pallestrini E, Santelli A, Vitale V, Marchetti G, Rosso R. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study. Am J Clin Oncol. 2001 Dec;24(6):618-22.</citation>
    <PMID>11801767</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First People's Hospital of Foshan</investigator_affiliation>
    <investigator_full_name>Tao Xu</investigator_full_name>
    <investigator_title>Foshan head and neck group</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

